Effects of iron manipulation on trace elements level in a model of colitis in rats

Barollo, Michela; D’Incà, R.; Scarpa, Marco; Medici,; Cardin, R.; Bortolami, Marina; Ruffolo, Cesare; Angriman, Imerio; Sturniolo, Giacomo Carlo

doi:10.3748/wjg.v11.i28.4396

Cited by 15 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other antioxidants in addition to EDTA have also been shown to inhibit TNF-alpha, IL-6, and IL-8 in liver diseases. 31,32 Further evidence of the diminution in liver damage with EDTA therapy is the change in Cp activity. It has been established that a diminution of its antioxidant activity is correlated with hepatic damage.…”

Section: Discussionmentioning

confidence: 98%

Ethylenediaminetetraacetic acid induces antioxidant and anti-inflammatory activities in experimental liver fibrosis

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Ethylenediaminetetraacetic acid induces antioxidant and anti-inflammatory activities in experimental liver fibrosis

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Besides prevention of anemia recurrence, it is of great importance to avoid iron overload, which may occur when ferritin levels are over 500 mcg/L and transferrin saturation is over 50% (8) . Iron overload not only is toxic but also can affect and worsen the inflammatory status, thereby increasing intestinal mucosa permeability, activating NF-kB and recruiting neutrophils (2,17) .…”

Section: Discussionmentioning

confidence: 99%

TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose

Sobrado¹,

Cançado

Sobrado

et al. 2015

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Objectives -Anemia is the most common hematological alteration in patients with Crohn's disease, and is frequently related to intestinal inflammatory activity. Its cause is multifactorial and mostly associated with absolute iron deficiency (iron deficiency anemia) and/or functional iron deficiency (inflammation anemia or anemia of chronic disease). It may also be identified through other causes, such as folic acid or vitamin B12 deficiency and secondary to adverse effects from medications (salicylic derivatives and immunosuppressive drugs). In the present study, patients with active Crohn's disease and anemia were evaluated and treated with intravenous ferric carboxymaltose. We discuss the therapeutic schemes (doses), safety, results and improvement of quality of life. Methods -In the present prospective study, 10 consecutive patients with Crohn's disease, with moderate to severe activity, with anemia (Hb: 6.7 to 10 g/dL), who were attended between March 2014 and March 2015, were evaluated. Six (60%) were men and four were women, all with moderate or severe anemia (hemoglobin <10 g/dL). They were treated with a maximum of three intravenous infusions of 1000 mg of ferric carboxymaltose, of at least 15 minutes in duration. It was also sought to correlate the inflammatory Crohn's disease activity degree (measured using the Crohn's Disease Activity Index, CDAI) and C-reactive protein level with the severity of anemia. The primary outcome was an increase in Hb of ≥2 g/dL and the secondary outcome was the normalization of anemia (Hb ≥12 g/dL for women and ≥13 g/dL for men) and the improvement in quality of life seen 12 weeks after the last application of carboxymaltose. Results -Among the 10 patients studied, parenteral iron supplementation was administered in three cases during hospitalization and the others received this on an outpatient basis. The total iron dose ranged from 1,000 to 2,000 mg, with an average of 1,650 mg. Crohn's disease activity measured using CDAI and C-reactive protein correlated with the intensity of anemia. An increase of 2 g/dL occurred in eight (80%) patients after 12 weeks and normalization of anemia was found in seven (70%) patients. Improvements in quality-of-life scores were found for all (100%) patients after 12 weeks. Carboxymaltose was well tolerated. Three patients presented adverse reactions (two with nausea and one with headache) of mild intensity. Conclusions -Anemia is a frequent complication for Crohn's disease patients. Intravenous iron therapy has been recommended for Crohn's disease patients, because for these patients, oral iron absorption is very limited. This is because of the inflammatory state and "blocking" of iron entry into enterocytes through hepcidin action on ferroportin, along with the elevated rates of gastrointestinal adverse events that compromise adherence to treatment and possibly aggravate the intestinal inflammatory state. The degree of Crohn's disease activity, as measured using CDAI and C-reactive protein, correlates with the severity of anemia....

show abstract

“…Studies by Borollo and coworkers from Italy, in a rodent colitis model, show both dietary iron deprivation and pharmacological iron chelation to decrease DNA damage rate [17,18]. Yoshiji and coworkers found iron deficiency to inhibit development of pre-neoplastic lesions and production of 8-OHdG in rat livers [19].…”

Section: Discussionmentioning

confidence: 99%

Body iron is a contributor to oxidative damage of DNA

Tuomainen

Loft

Nyyssönen

et al. 2007

Free Radical Research

View full text Add to dashboard Cite

The transition metal iron is catalytically highly active in vitro, and not surprisingly, body iron has been suggested to promote oxidative stress in vivo. In the current analysis we studied the association of serum ferritin concentration and serum soluble transferrin receptor concentration with daily urinary 8-hydroxydeoxyguanosine excretion, a marker of oxidative stress, in 48 mildly dyslipidemic men in East Finland. In multivariate linear regression analyses allowing for age, smoking, body mass index and physical exercise, serum ferritin concentration predicted the excretion rate at B ¼ 0.17 (95% CI 0.08-0.26, P ¼ 0.001), and serum soluble transferrin receptor to ferritin concentration ratio (TfR/ferritin) predicted the excretion rate at B ¼ 20.13 (95% CI 2 0.21 to 20.05, P ¼ 0.002). Our data suggest that body iron contributes to excess oxidative stress already at noniron overload concentrations in these subjects.

show abstract

Effects of iron manipulation on trace elements level in a model of colitis in rats

Abstract: Iron deprivation diminishes the severity of DNBS colitis while supplementation worsens colitis. Zinc and copper status are modified by iron manipulation.

Cited by 15 publications

References 24 publications

Ethylenediaminetetraacetic acid induces antioxidant and anti-inflammatory activities in experimental liver fibrosis

Ethylenediaminetetraacetic acid induces antioxidant and anti-inflammatory activities in experimental liver fibrosis

TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose

Body iron is a contributor to oxidative damage of DNA

Contact Info

Product

Resources

About